A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients

NCT03013504 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

503

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Breast Cancer

Interventions

DRUG: HD201
DRUG: Herceptin
DRUG: Docetaxel
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

Prestige Biopharma Limited